GlassScriptPhysician profile
Katie Lynnette Kisner
NPI 1811503923
$3,623.12
in general payments reported to CMS, 2019-2025
22 companies · $785 in 2025
The $785 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $509 · 2022: $728 · 2023: $1,079 · 2024: $522 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.75 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.37 | 2021-2025 | |
| Alkermes, INC. | $469.39 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $392.71 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $294.25 | 2023-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $243.62 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $183.17 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $163.65 | 2022-2024 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $141.33 | 2022-2024 | Austedo Xr, Austedo |
| Indivior INC. | $107.80 | 2021-2024 | Sublocade, Perseris |
| Lundbeck LLC | $93.62 | 2021-2023 | Rexulti |
| Abiomed | $87.02 | 2024 | Impella |
| Takeda Pharmaceuticals U.S.A., INC. | $65.37 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $60.29 | 2021-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $48.30 | 2024-2025 | Fanapt |
| Hikma Pharmaceuticals USA | $42.00 | 2023 | Kloxxado |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $38.32 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $37.79 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $29.42 | 2023-2024 | Ingrezza |
| Braeburn INC. | $18.95 | 2025 | Brixadi |
| Jazz Pharmaceuticals INC. | $14.24 | 2021 | |
| Neos Therapeutics, LP | $14.07 | 2022 | |
| Eisai INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Kisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.